Bayer presents new data across oncology portfolio at the 2023 ASCO Annual Meeting
25 May 2023 | 13:59 PM Europe/Amsterdam Not intended for U.S. and UK Media Summary Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride data in metastatic castration-resistant prostate cancer (mCRPC) / …
Bayer presents new data across oncology portfolio at the 2023 ASCO Annual Meeting Read More »









